InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $16.730 0.63 (3.63%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,685 Appendix 3B - quotation of escrow shares, issue of options 15 Nov 2019 8:24AM $1.850 $16.730 risen by 804.32%
$5,685 Program Update - Q3 2019 4 Nov 2019 8:20AM $1.590 $16.730 risen by 952.20%
$5,685 Telix and AusHealth Partner for Lung, Ovarian Cancer 30 Oct 2019 8:13AM $1.625 $16.730 risen by 929.54%
$5,685 Sales Note to accompany Appendix 4C 29 Oct 2019 8:18AM $1.550 $16.730 risen by 979.35%
$5,685 Appendix 4C - September 2019 quarter 29 Oct 2019 8:18AM $1.550 $16.730 risen by 979.35%
$5,685 Notice of release of securities from Mandatory Escrow 29 Oct 2019 8:17AM $1.550 $16.730 risen by 979.35%
$5,685 Telix and GE data - 68Ga supply for prostate cancer imaging 14 Oct 2019 8:29AM $1.395 $16.730 risen by 1,099.28%
$5,685 David Cade appointed Chief Business Officer and Head of IR 7 Oct 2019 8:26AM $1.340 $16.730 risen by 1,148.51%
$5,685 Telix to Acquire European Production Facility 3 Oct 2019 8:24AM $1.420 $16.730 risen by 1,078.17%
$5,685 App 3Y - Change in interests following exercise of options 17 Sep 2019 10:55AM $1.405 $16.730 risen by 1,090.75%
$5,685 App 3B - issue of shares following exercise of options 17 Sep 2019 10:54AM $1.405 $16.730 risen by 1,090.75%
$5,685 Telix to Commence Renal Cancer Imaging Study in Japan 30 Aug 2019 8:13AM $1.385 $16.730 risen by 1,107.94%
$5,685 FDA Pre-NDA Meeting Outcomes - TLX591-CDx illumet 28 Aug 2019 8:12AM $1.350 $16.730 risen by 1,139.26%
$5,685 App 3B for issue of shares under SPP - correction at Q8 23 Aug 2019 12:29PM $1.445 $16.730 risen by 1,057.79%
$5,685 Appendix 4D and Financial Report for half-year to 30 June 19 22 Aug 2019 4:47PM $1.435 $16.730 risen by 1,065.85%
$5,685 Appendix 3B - issue of shares under Share Purchase Plan 22 Aug 2019 4:37PM $1.435 $16.730 risen by 1,065.85%
$5,685 First Australian Patient Dosed in ZIRCON Phase III Trial 20 Aug 2019 1:42PM $1.330 $16.730 risen by 1,157.89%
$5,685 Telix Pharmaceuticals announces results of successful SPP 19 Aug 2019 3:46PM $1.315 $16.730 risen by 1,172.24%
$5,685 ENHANCING Prostate Cancer Clinical Study - Investor Overview 8 Aug 2019 8:25AM $1.410 $16.730 risen by 1,086.52%
$5,685 Telix and GenesisCare Commence Prostate Cancer Study 8 Aug 2019 8:24AM $1.410 $16.730 risen by 1,086.52%
$5,685 Collaboration with DKFZ for Image-Guided Prostate Surgery 5 Aug 2019 8:24AM $1.540 $16.730 risen by 986.36%
$5,685 Lancet Publication Demonstrates Superiority of PSMA Imaging 1 Aug 2019 10:01AM $1.410 $16.730 risen by 1,086.52%
$5,685 Telix and Merck Group Combination Therapy Collaboration 1 Aug 2019 8:25AM $1.410 $16.730 risen by 1,086.52%
$5,685 Sales Note to Accompany June 2019 Quarter Appendix 4C 31 Jul 2019 9:59AM $1.495 $16.730 risen by 1,019.06%
$5,685 Appendix 4C - June 2019 Quarter 31 Jul 2019 9:57AM $1.495 $16.730 risen by 1,019.06%

776 - 800 of 948 results

Page 32 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.